Evidence map›Paper›PMID 41548170›Full record

Trial reportInternational journal of hematology2026

Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3.

Koji Izutsu, Daigo Akahane, Tomomi Toubai, Toko Saito, Yuko Mishima, Tomoaki Fujisaki, Momoko Nishikori, Takahiro Kumode, Youko Suehiro, Kenji Ishitsuka and 5 more

Registry-linked trialAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04542824 (Safety and Preliminary Efficacy of Epcoritamab), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04542824 phase1 / phase2active not recruitingnot on this map

Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A Phase 1/2, Open-Label, Dose-Escalation Trial With Expansion Cohorts

TypeinterventionalSponsorGenmabRan2020 to 2027Enrolled78ConditionsDiffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular LymphomaArmsEpcoritamab (monotherapy), Epcoritamab, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, Gemcitabine and oxaliplatin, Epcoritamab (maintenance)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Koji IzutsuDepartment of Hematology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. kizutsu@ncc.go.jp.ORCID http://orcid.org/0000-0001-9129-8057
Daigo AkahaneDepartment of Hematology, Tokyo Medical University, Tokyo, Japan.
Tomomi ToubaiDepartment of Internal Medicine III, Division of Hematology and Cell Therapy, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Toko SaitoDepartment of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
Yuko MishimaDepartment of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Tomoaki FujisakiDepartment of Hematology, Japan Red Cross Society, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Momoko NishikoriDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Takahiro KumodeDepartment of Hematology and Rheumatology, Kindai University, Osaka, Japan.
Youko SuehiroDepartment of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Kenji IshitsukaDepartment of Hematology and Rheumatology, Kagoshima University, Kagoshima, Japan.
Poliana PatahAbbVie, North Chicago, IL, USA.
Ami TakahashiGenmab, Tokyo, Japan.
Barbara D'Angelo MånssonGenmab, Copenhagen, Denmark.
Elena FavaroGenmab, Copenhagen, Denmark.
Noriko FukuharaDepartment of Hematology, Tohoku University, Sendai, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe CD3xCD20 bispecific antibody epcoritamab demonstrated deep, durable responses with manageable safety in relapsed/refractory (R/R) follicular lymphoma (FL) in EPCORE NHL-3 (phase 1/2; NCT04542824). This analysis evaluated 3-year follow-up outcomes in Japanese patients.

methodsAdults with CD20 + FL and ≥ 2 prior lines of therapy (LOTs) received subcutaneous epcoritamab (0.16/0.8-mg step-up doses; 48-mg full doses) until disease progression or death. The primary endpoint was overall response rate (ORR).

resultsTwenty-one patients received epcoritamab (median age: 65 years; median prior LOTs: 4; 57.1% double refractory; 57.1% progressed within 24 months of any first-line treatment). At a median follow-up of 35 months, the ORR was 95.2% and the complete response (CR) rate was 76.2%. Median duration of response, duration of CR, progression-free survival, and overall survival were not reached. At 3 years, 66.7% and 93.3% of complete responders remained progression-free and alive, respectively. Minimal residual disease negativity was achieved in 88.9% (16/18) of evaluable patients. Common treatment-emergent adverse events included cytokine release syndrome (90.5%) and injection-site reaction (71.4%), all predominantly grade 1-2 and occurring in early treatment cycles, and none fatal.

conclusionsEpcoritamab monotherapy provided durable long-term remission with favorable safety in Japanese patients with R/R FL over 3 years of follow-up.

Indexed as

Antibodies, BispecificLymphoma, FollicularAdultAgedAged, 80 and overEast Asian PeopleFemaleFollow-Up StudiesHumansJapanMaleMiddle AgedRecurrenceTime FactorsTreatment OutcomeAntibodies, BispecificBispecific antibodiesClinical trialFollicular lymphomaNon-Hodgkin lymphoma

Identifiers

PMID41548170
PMCPMC13171670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.